Median Technologies and PASREL-Imagerie Join Forces to Deliver Smart Imaging Biomarkers Supporting the Development of New Oncology Drugs in Precision Medicine
2023年12月15日 - 1:45AM
ビジネスワイヤ(英語)
- The association aims to develop and implement smart imaging
biomarkers to better understand the mechanism of action (MOA) of
oncology drugs and collect more evidence of efficiency in early
phase clinical trials.
- The agreement strengthens Median’s iCRO capabilities to support
the biopharmaceutical industry’s move toward precision
medicine.
- The agreement confirms PASREL-Imagerie's ability to derisk
medical innovations by providing pharmaceutical companies with its
in vivo clinical imaging expertise.
Regulatory News:
Median Technologies (Paris:ALMDT) and PASREL-Imagerie, announce
today the signing of an agreement to deliver cutting-edge imaging
biomarkers for the development of new oncology drugs in the era of
precision medicine. By leveraging its expertise in medical imaging,
PASREL-Imagerie will bring its know-how and support to Median in
the implementation of advanced imaging biomarkers for early phase
oncology trials. New capabilities resulting from this agreement
create a strong and unique differentiator for Median’s iCRO
offering, compared to the offerings of other imaging vendors
targeting the biopharmaceutical industry.
Whereas oncology clinical trials today rely primarily on
relatively standard imaging assessments, the ability to implement
advanced imaging biomarkers - including molecular imaging -
specifically linked to the drug’s mechanism of action would help
better understand the biological effect of each drug and collect
additional evidence of efficiency during the early phases of
clinical trials. The resulting knowledge would enable the
biopharmaceutical industry to develop new drugs more effectively,
while making the drug development cycle safer and shorter.
PASREL-Imagerie brings together 33 technical platforms and has a
long-lasting experience of industry partnerships to support
innovative drug developments. PASREL-Imagerie has unique scientific
and medical expertise in the entire imaging value chain, from
radiotracer production to image acquisition and processing for
statistical and quantitative analysis.
“By creating Imaging Lab in 2022, we showed our commitment to
providing advanced imaging technologies to the biopharmaceutical
industry. The agreement signed with PASREL-Imagerie aims to
implement relevant and smart imaging biomarkers to assess new drug
mechanisms of action and provide preliminary efficacy insights in
early phase clinical trials. For us, this ability will be a unique
point of differentiation compared to imaging vendors providing only
classical imaging readouts,” said Nicolas Dano, COO iCRO at Median
Technologies. “Through the association, Median will strengthen its
superior expertise in medical imaging technologies with a
scientific approach paving the way for fruitful discussions with
translational and biomarker scientists as well as medical directors
involved in the early phases of drug development. This agreement
clearly demonstrates Median’s commitment to supporting the rise of
precision medicine,” he added.
“This alliance with Median Technologies, a key player in imaging
for clinical trials, strengthens PASREL-Imagerie in its mission to
support pharmaceutical industry by promoting its scientific
expertise and its technology platforms for medical imaging”
mentioned Vincent Lebon, Director of PASREL-Imagerie and Department
Chief at CEA. “We have here a synergy between two major players of
the drug development value chain to accelerate and derisk medical
innovation for patient benefit”.
About Median Technologies: Median Technologies provides
innovative imaging solutions and services to advance healthcare for
everyone. We harness the power of medical images by using the most
advanced Artificial Intelligence technologies, to increase the
accuracy of diagnosis and treatment of many cancers and other
metabolic diseases at their earliest stages and provide insights
into novel therapies for patients. Our iCRO solutions for medical
image analysis and management in oncology trials and eyonis™, our
AI/ML tech-based suite of software as medical devices (SaMD), help
biopharmaceutical companies and clinicians to bring new treatments
and diagnose patients earlier and more accurately. This is how we
are helping to create a healthier world.
Founded in 2002, based in Sophia-Antipolis, France, with a
subsidiary in the US and another one in Shanghai, Median has
received the label “Innovative company” by the BPI and is listed on
Euronext Growth market (Paris). FR0011049824– ticker: ALMDT. Median
is eligible for the French SME equity savings plan scheme
(PEA-PME). For more information: www.mediantechnologies.com
About PASREL-lmagerie: PASREL-Imagerie is a French
consortium of four medical imaging research platforms at CEA
Paris-Saclay (IDMIT, MIRCen, NeuroSpin and SHFJ). These platforms
have been working together on ambitious projects for several years,
bringing their expertise and technological platforms in
translational in vivo imaging to the service of industry. More
information on www.pasrel-imagerie.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231214119683/en/
Median Technologies Median Technologies Emmanuelle
Leygues Head of Corporate Marketing & Financial Communications
+33 6 10 93 58 88 emmanuelle.leygues@mediantechnologies.com
Press - ALIZE RP Caroline Carmagnol +33 6 64 18 99 59
median@alizerp.com
Investors - ACTIFIN Ghislaine Gasparetto +33 6 21 10 49
24 ggasparetto@actifin.fr
PASREL-Imagerie Ali Aït-Ikhlef Business Development
Manager ali.aitikhlef@cea.fr + 33 6 17 86 48 70
Median Technologies (EU:ALMDT)
過去 株価チャート
から 4 2024 まで 5 2024
Median Technologies (EU:ALMDT)
過去 株価チャート
から 5 2023 まで 5 2024